New International President Takes Reins of MSF 16/09/2019 Editorial team Trauma surgeon and veteran field worker, Christos Christou, has taken over the Médecins Sans Frontières (MSF) reins as International President, following his election by the organization’s International General Assembly last June. Christou, former president of the MSF Greece Board of Directors, will be faced with the leadership challenges of an organization that has grown from […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Ebola Outbreak Marks 1 Year With Huge Funding Gap, Questions On Vaccine Strategy 01/08/2019 David Branigan Thursday, 1 August, marked the one-year anniversary of the Ebola outbreak in the Democratic Republic of the Congo (DRC), as daily reports of new infections, including 3 more cases in Goma along DRC’s border with Rwanda, fueled new concerns about regional spread of the deadly disease. Meanwhile, the World Health Organization called on international donors […] Continue reading -> React Africa 2019: Universal Health Coverage Can Help Combat Antimicrobial Resistance 25/07/2019 Geoffrey Kamadi NAIROBI – Neonatal sepsis is one of the leading causes of newborn deaths globally, and increasing pathogen resistance to available first-line treatments is a prime example of rising antimicrobial resistance. That is why the Global Antibiotic Research and Development Partnership (GARDP) – a non-profit research organisation that develops new or improved antibiotic treatments – is […] Continue reading -> Making Tough Vaccine Choices Amidst The Ebola Public Health Emergency 24/07/2019 Editorial team WHO’s declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) a Public Health Emergency of International Concern has been shadowed by growing questions over vaccine strategy in a crisis that has dragged on for over a year, and now threatens to spread across borders. Until now, a ring vaccination strategy focusing […] Continue reading -> Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 Editorial team, Elaine Ruth Fletcher & David Branigan WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Posts navigation Older postsNewer posts
How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Ebola Outbreak Marks 1 Year With Huge Funding Gap, Questions On Vaccine Strategy 01/08/2019 David Branigan Thursday, 1 August, marked the one-year anniversary of the Ebola outbreak in the Democratic Republic of the Congo (DRC), as daily reports of new infections, including 3 more cases in Goma along DRC’s border with Rwanda, fueled new concerns about regional spread of the deadly disease. Meanwhile, the World Health Organization called on international donors […] Continue reading -> React Africa 2019: Universal Health Coverage Can Help Combat Antimicrobial Resistance 25/07/2019 Geoffrey Kamadi NAIROBI – Neonatal sepsis is one of the leading causes of newborn deaths globally, and increasing pathogen resistance to available first-line treatments is a prime example of rising antimicrobial resistance. That is why the Global Antibiotic Research and Development Partnership (GARDP) – a non-profit research organisation that develops new or improved antibiotic treatments – is […] Continue reading -> Making Tough Vaccine Choices Amidst The Ebola Public Health Emergency 24/07/2019 Editorial team WHO’s declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) a Public Health Emergency of International Concern has been shadowed by growing questions over vaccine strategy in a crisis that has dragged on for over a year, and now threatens to spread across borders. Until now, a ring vaccination strategy focusing […] Continue reading -> Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 Editorial team, Elaine Ruth Fletcher & David Branigan WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Posts navigation Older postsNewer posts
Ebola Outbreak Marks 1 Year With Huge Funding Gap, Questions On Vaccine Strategy 01/08/2019 David Branigan Thursday, 1 August, marked the one-year anniversary of the Ebola outbreak in the Democratic Republic of the Congo (DRC), as daily reports of new infections, including 3 more cases in Goma along DRC’s border with Rwanda, fueled new concerns about regional spread of the deadly disease. Meanwhile, the World Health Organization called on international donors […] Continue reading -> React Africa 2019: Universal Health Coverage Can Help Combat Antimicrobial Resistance 25/07/2019 Geoffrey Kamadi NAIROBI – Neonatal sepsis is one of the leading causes of newborn deaths globally, and increasing pathogen resistance to available first-line treatments is a prime example of rising antimicrobial resistance. That is why the Global Antibiotic Research and Development Partnership (GARDP) – a non-profit research organisation that develops new or improved antibiotic treatments – is […] Continue reading -> Making Tough Vaccine Choices Amidst The Ebola Public Health Emergency 24/07/2019 Editorial team WHO’s declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) a Public Health Emergency of International Concern has been shadowed by growing questions over vaccine strategy in a crisis that has dragged on for over a year, and now threatens to spread across borders. Until now, a ring vaccination strategy focusing […] Continue reading -> Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 Editorial team, Elaine Ruth Fletcher & David Branigan WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Posts navigation Older postsNewer posts
React Africa 2019: Universal Health Coverage Can Help Combat Antimicrobial Resistance 25/07/2019 Geoffrey Kamadi NAIROBI – Neonatal sepsis is one of the leading causes of newborn deaths globally, and increasing pathogen resistance to available first-line treatments is a prime example of rising antimicrobial resistance. That is why the Global Antibiotic Research and Development Partnership (GARDP) – a non-profit research organisation that develops new or improved antibiotic treatments – is […] Continue reading -> Making Tough Vaccine Choices Amidst The Ebola Public Health Emergency 24/07/2019 Editorial team WHO’s declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) a Public Health Emergency of International Concern has been shadowed by growing questions over vaccine strategy in a crisis that has dragged on for over a year, and now threatens to spread across borders. Until now, a ring vaccination strategy focusing […] Continue reading -> Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 Editorial team, Elaine Ruth Fletcher & David Branigan WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Posts navigation Older postsNewer posts
Making Tough Vaccine Choices Amidst The Ebola Public Health Emergency 24/07/2019 Editorial team WHO’s declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) a Public Health Emergency of International Concern has been shadowed by growing questions over vaccine strategy in a crisis that has dragged on for over a year, and now threatens to spread across borders. Until now, a ring vaccination strategy focusing […] Continue reading -> Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 Editorial team, Elaine Ruth Fletcher & David Branigan WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Posts navigation Older postsNewer posts
Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 Editorial team, Elaine Ruth Fletcher & David Branigan WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Posts navigation Older postsNewer posts
ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 Editorial team, Elaine Ruth Fletcher & David Branigan WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Posts navigation Older postsNewer posts
New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 Editorial team, Elaine Ruth Fletcher & David Branigan WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Posts navigation Older postsNewer posts
Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Posts navigation Older postsNewer posts
Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> Posts navigation Older postsNewer posts